(Q35114341)

6 August 2017

title

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer (English)

1 reference

6 August 2017

1 reference

10

Anil K Sood

1 reference

6 August 2017

Aparna A Kamat

1

1 reference

6 August 2017

Donna Coffey

2

1 reference

6 August 2017

William M Merritt

3

1 reference

6 August 2017

Elizabeth Nugent

4

1 reference

6 August 2017

Diana Urbauer

5

1 reference

6 August 2017

Yvonne G Lin

6

1 reference

6 August 2017

Creighton Edwards

7

1 reference

6 August 2017

Russell Broaddus

8

1 reference

6 August 2017

Robert L Coleman

9

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

6 August 2017

1 reference

6 August 2017

volume

115

1 reference

6 August 2017

issue

12

1 reference

6 August 2017

page(s)

2684-2692

1 reference

6 August 2017

cites work

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

EphA2 overexpression is associated with angiogenesis in ovarian cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

Eph receptor signalling casts a wide net on cell behaviour

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

EphA2 expression is associated with aggressive features in ovarian carcinoma

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

Differential regulation of EphA2 in normal and malignant cells

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

The receptor tyrosine kinases: role in cancer progression.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

Eph receptors and ephrin ligands: embryogenesis to tumorigenesis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2).

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

EphA2 overexpression causes tumorigenesis of mammary epithelial cells.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

Overexpression of the EphA2 tyrosine kinase in prostate cancer.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139331

Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance

27 September 2018

1 reference

12 December 2020

Steroid hormone receptor content and lymph node status in endometrial cancer

1 reference

12 December 2020

Endometrial carcinoma

1 reference

12 December 2020

Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group

1 reference

12 December 2020

Identifiers

DOI

10.1002/CNCR.24335

1 reference

6 August 2017

1 reference

6 August 2017

1 reference